Futura Medical PLC AGM Statement (9942H)
14 June 2017 - 4:00PM
UK Regulatory
TIDMFUM
RNS Number : 9942H
Futura Medical PLC
14 June 2017
For immediate release 14 June 2017
Futura Medical plc
("Futura" or "the Company")
AGM Statement
Futura Medical plc (AIM: FUM), the innovative healthcare company
focused on advanced transdermal technology, will hold its Annual
General Meeting ("AGM") in London later today.
Futura's Chairman, John Clarke, will deliver the following
statement at the meeting:
"The development and commercialisation of our product pipeline
continues apace and we have made good progress in the year to date
especially across our sexual health products: MED2002 and
CSD500.
"As announced at the end of last month, we have received
constructive feedback from US and UK regulatory authorities on the
clinical and regulatory pathway for MED2002, our topical gel for
erectile dysfunction. As a result of this feedback we expect our
Phase III programme of MED2002 to proceed as planned, with the
first patient dosed in Q4 this year. We continue to receive
significant commercial interest in MED2002 from potential licensing
partners and negotiations are ongoing.
"On CSD500, our novel erectogenic condom, we are currently
assisting all our EU licensing partners wherever required with
their launch plans in a number of countries. In addition, we have
in production two manufacturing orders from our licensing partner
for the Middle East and North Africa, following its launch of
CSD500 in Saudi Arabia earlier this year.
"We continue in discussions on the out-licensing of our two pain
relief products, TIB200 and TPR100, with potential licensing
partners. We look forward to providing an update on these
discussions, and on other corporate developments, in due
course.
"Futura continues to benefit from a strong financial position
and we look forward to the year ahead with confidence."
For any further information please contact:
Futura Medical plc
James Barder, Chief Executive Tel: +44 (0)1483 685
670
mail to: james.barder@futuramedical.com www.futuramedical.com
N+1 Singer (Nominated Adviser
and Broker)
Aubrey Powell / Liz Yong Tel:+44 (0) 20 7496 3000
For media enquiries please
contact:
Buchanan
Mark Court / Sophie Cowles Tel: +44 (0)20 7466 5000
/ Stephanie Watson
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops
innovative products for consumer healthcare. The Company is
developing a portfolio of products and its strategy is to license
their manufacture and distribution to major pharmaceutical and
healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMUOANRBWANAAR
(END) Dow Jones Newswires
June 14, 2017 02:00 ET (06:00 GMT)
Futura Medical (LSE:FUM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Futura Medical (LSE:FUM)
Historical Stock Chart
From Apr 2023 to Apr 2024